Ligelizumab treatment for severe asthma: learnings from the clinical development programme

OBJECTIVE: Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. This multi‐centre, randomised, double‐blind study was designe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Immunology
Main Authors: Trischler, Jordis, Bottoli, Ivan, Janocha, Reinhold, Heusser, Christoph, Jaumont, Xavier, Lowe, Phil, Gautier, Aurelie, Pethe, Abhijit, Woessner, Ralph, Zerwes, Hans‐Günter, Zielen, Stefan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958305/
https://ncbi.nlm.nih.gov/pubmed/33747510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1255
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados